A MOTAMEDZADEH; M AFKHAMI ARDEKANI; M RASHIDI
Volume 14, Issue 4 , January and February 2008, , Pages 205-210
Abstract
Background and Purpose: Type II diabetes is a chronic disease characterized by insulin resistance, impaired insulin secretion and increased hepatic glucose production. Metformin is a biguanide which reduces the production of hepatic glucose and is able to increase the sensitivity of peripheral tissue ...
Read More
Background and Purpose: Type II diabetes is a chronic disease characterized by insulin resistance, impaired insulin secretion and increased hepatic glucose production. Metformin is a biguanide which reduces the production of hepatic glucose and is able to increase the sensitivity of peripheral tissue to insulin. This study was designed to investigate the effect of metformin on lipid profile and body weight.
Methods and Materials: In this clinical trial, 51 type II diabetic patients, admitted to Yazd Research Crnter of Diabetes, with FBS>150 mg/dl, Tg>200 mg/dl and BMI>25 kg/m2 and no previous history of metformin use, were selected. They were give metformin for one month, 1 gr a day; after one month, they were assessed for BMI, 2hPP and FBS. Due to gastrointestinal complications, 4 patients were excluded from the research. Paired t-test was used in comparing the befor-after response means.
Results: After using metformin, cholesterole and triglyceride dropped by 9.26±2.1 and 54.02±50.51 mg/dl respectively. Also, metformin induced a significant decrease in FBS, 2h postprandial glucose and body weight. No significant relationship was observed between the mean weight loss and factors of age and sex.
Conclusion: In the present study, metformin reduced blood sugar, lipids and body weight.
A MAKHLOGH; M JAMSHIDI; V MOKHBERI
Volume 13, Issue 1 , March and April 2006, , Pages 14-18
Abstract
Background and purpose: Hyperlipidemia is one of the most important cardiovascular risk factors in hemodialysis patients. As adequate amount of carnation is essential for fatty acids metabolism and prevention of hyperlipidemia, This research was conducted to study the effect of carnitine on serum lipids ...
Read More
Background and purpose: Hyperlipidemia is one of the most important cardiovascular risk factors in hemodialysis patients. As adequate amount of carnation is essential for fatty acids metabolism and prevention of hyperlipidemia, This research was conducted to study the effect of carnitine on serum lipids in hemodialysis patients.
Methods and Materials: 20 patients with at least 3 months hemodialysis duration participated in this double-blind clinical trial. Randomly and equally, they were divided into two (case and control) groups. Cases received 1g carnitine and controls received placebo daily. Cholesterol and Triglyceride levels were measured prior to the study as well as 3 and 6 months after administration. SPSS package and ANOVA, t-test and chi-squre tests were used far analysis.
Results: There were not significant difference in mean of cholesterol and triglyceride levels in two groups as well as in repeated measurements. Also, no significaut changes were observed in each group 3 and 6 months after administration.
Conclusion: Carnitine did not have any effect on serum lipids in hemodialysis patients.